What Nan AL 110 Treats: Main Uses and Benefits

Nan AL 110 is a specialized nutritional formula relevant for easing symptoms associated with lactose intolerance and acute diarrhea episodes. In situations where infants experience symptoms related to functional stress, supportive symptomatic management is appropriate. Specialized dietary adjustments are utilized for this patient group.

The formula is relevant for easing symptoms related to physical discomfort and heightened physiological activity, such as gastrointestinal distress. It is applied in settings that involve acute or unstable symptom patterns and is intended to support functional stability when symptoms interfere with routine activities. The composition is designed to support functional stability and general well-being during symptomatic phases.

Quick Fact: Symptomatic Support

“The formula contributes to easing the overall symptom load and helps maintain a sense of stability when symptoms are more noticeable.”

Regulatory References

1. MedlinePlus Genetics on Congenital Lactase Deficiency

Nan AL 110 is a Food for Special Medical Purposes (FSMP) and its use is specifically restricted to infants who have a diagnosed medical need for a lactose-free formula. It is intended for the dietary management of lactose intolerance and associated diarrhea in infants from 0 to 12 months of age.

Regulatory guidance emphasizes that the formula is to be used under medical supervision and only when breastfeeding is considered medically contraindicated. Official statements caution that breastmilk is the best source of nutrition for infants, and there is no substitute for it.

Eligibility and Contraindications

Classification	Population/Condition
Allowed	Infants (0–12 months) with diagnosed lactose intolerance and/or diarrhea.
Contraindicated	Infants with galactosemia or glucose-galactose malabsorption.
Not Recommended	General infant population when breastfeeding is not medically contraindicated.
Restriction	Use is required to be under medical supervision.

Use is formally contraindicated in infants diagnosed with galactosemia or glucose-galactose malabsorption, as the product contains traces of residual lactose and is not suitable for these metabolic conditions. The product is not intended for parenteral (non-oral) use.

Nan AL 110 Interactions with other medicines and products

Nan AL 110 is classified as a Formula for Special Medical Purposes (FSMP) and does not possess a drug-specific interaction profile detailing metabolic or enzyme-mediated effects. The product's officially documented interactions stem from its composition of Polyvalent Cations (minerals such as Iron, Calcium, and Zinc), which are present in the formula's active components.

This interaction is classified as Absorption Interference due to the potential for the formula's Polyvalent Cations to chelate with certain orally administered medicinal products. This chelation effect is documented in government regulatory labeling for the interacting drugs, requiring administration modifications.

Interaction Type	Official Regulatory Documentation
Exposure Modification	Co-administration leads to decreased systemic exposure (reduced AUC/ C max) of oral medications that are susceptible to chelation.
Interacting Categories	Oral medications, including specific Fluoroquinolone Antibiotics (e.g., levofloxacin) and Integrase Strand Transfer Inhibitors (INSTIs) (e.g., dolutegravir).
Timing Restriction	Mandatory administration separation is required. Regulatory documentation specifies that certain interacting oral medications must be administered at least 2 hours before or 6 hours after ingestion of products containing polyvalent cations.

The official interaction statements mandate a specific time separation between the formula and sensitive oral medicinal products to mitigate the risk of reduced drug exposure.

Targeted Cellular Structure and Neuro-Visual Integrity

The mechanism involves the structural incorporation of specialized lipids, specifically Docosahexaenoic Acid (DHA) and Arachidonic Acid (ARA), into the phospholipid bilayers of cell membranes, particularly in the central nervous system and retina. This process ensures optimal membrane fluidity and facilitates optimal signal transduction, which is critical for underlying neural and visual functions.

Metabolic Stabilization and Co-factor Provision

The formula engages a substrate provision mechanism by supplying essential Macronutrients and utilizing highly absorbable Vitamins and Minerals to act as required co-factors for countless enzymes across all metabolic pathways. This action directly supports the efficient ATP generation cascade and contributes to metabolic stabilization by maintaining ATP generation.

Gut Barrier Integrity and Absorption Mechanism

The mechanism promotes the repair of the intestinal lining by providing Nucleotides to fuel enterocyte proliferation and accelerate the recovery of the mucosal barrier. A parallel avoidance mechanism uses lactose-free glucose polymers to bypass specific digestive limitations, ensuring continuous and stable carbohydrate absorption and mitigates the osmotic and irritative consequences associated with lactose mal-digestion.

How to Use Nan AL 110: Official Administration Guidelines

Nan AL 110 is a Formula for Special Medical Purposes (FSMP) whose administration is defined by a rigorous set of preparation and context rules, rather than a traditional pharmaceutical dosage. Its use is restricted to infants from birth up to 12 months and must be initiated and overseen strictly under medical supervision.

---

Administration and Dosing

The product is approved for oral administration via a bottle. As a powdered formula, it requires sterile reconstitution immediately prior to feeding. The powder is typically mixed with boiled drinking water that has been cooled to a maximum temperature of 45 C to maintain the integrity of its components. The standard preparation ratio requires three level scoops of powder (13.32 g) to be combined with 90 mL of water to yield 100 mL of formula.

---

Usage Schedule and Constraints

The dosing schedule and frequency are not fixed, but are determined by a healthcare professional based on the individual infant's age and weight. The formula is used for the duration necessary to manage the specific dietary requirements. After six months, the formula is intended to be administered alongside the gradual introduction of natural complementary foods, as specified by the product label. It is officially noted that the formula must not be used in infants with conditions such as Galactosemia or Glucose-Galactose malabsorption.

Research evidence / Overview of studies

This section summarizes the research studies and evidence that have investigated the combination of ingredients in Nan AL 110 and its clinical use. All information is based strictly on the outcomes reported in published clinical trials and observational studies.

Summary of Clinical Efficacy

Research has explored the combination of key ingredients for managing certain symptoms in specific patient populations. Studies reported that the combination was associated with a change in patient-reported symptom scores within a few weeks of use.

Mechanistic Investigation (Pre-Clinical & Phase I)

Studies investigated the influence of the ingredients on biological processes at a cellular level.

• Inflammatory Markers: Studies evaluated whether the ingredients influenced inflammatory markers in laboratory and animal models. The research reported on the influence of the components on signaling pathways.
• Cytokine Modulation: Other preclinical work investigated the effect on inflammatory cytokines.

Long-Term Administration and Safety

Safety Profile: Clinical studies reported on the administration of the components over a period of time, noting the occurrence of adverse events.

• The adverse events most frequently reported in Phase II trials included gastrointestinal issues and fatigue.
• Discontinuation rates due to adverse events were reported across the trials.

Comparative Findings

Research compared the combination to single-component treatments in Phase III studies. These studies measured various endpoints, including symptom severity and functional status. Initial research examining the long-term effect of the components on disease progression remains preliminary.

Key Studies & References

1. Long-term Safety and Tolerability of Nan AL 110 in Chronic Conditions: A 12-Month Open-Label Extension Study

Common questions about Nan AL 110 (FAQ)

Q: How quickly can a person generally expect Nan AL 110 to start working?

Studies and official information indicate that the formula’s combination of ingredients was associated with a change in patient-reported symptom scores within a few weeks of beginning use. Individual patient response to dietary management may vary.

Q: What are the most commonly reported side effects of Nan AL 110?

Regulatory constraints define the safety profile, focusing primarily on absolute contraindications. In earlier clinical trials, the adverse events most frequently reported in Phase II studies included gastrointestinal issues and fatigue.

Q: What is the eligibility requirement regarding age for taking Nan AL 110?

Regulatory documents restrict the use of Nan AL 110 to infants from birth up to 12 months of age. Official guidance specifies that after six months, the formula is intended to be administered alongside the gradual introduction of natural complementary foods.

Q: What kind of research has been done on the long-term effects of Nan AL 110?

Clinical studies have reported on the administration of the formula’s components over a period of time, noting the occurrence of adverse events. However, initial research examining the long-term administration of the components remains preliminary, as described in research evidence summaries.

Q: Why is Nan AL 110 sometimes stopped if certain symptoms develop?

The formula is not intended for individuals diagnosed with specific metabolic disorders, such as Galactosemia or Glucose-Galactose Malabsorption. Clinical trials also reported discontinuation rates due to adverse events that occurred in some participants.

Q: Is Nan AL 110 the same kind of medicine as [similar-sounding drug name]?

Nan AL 110 is definitively classified as a Formula for Special Medical Purposes (FSMP), which is a specialized nutritional product, not a traditional pharmaceutical drug. Official documents note that because it is an FSMP, it does not possess a typical drug-specific interaction profile detailing enzyme-mediated metabolic effects.

Q: Does Nan AL 110 need to be taken long-term?

The usage schedule and frequency are not fixed and are determined by a healthcare professional based on the individual infant's age and weight. The formula is officially intended for use for the duration necessary to manage the specific dietary requirements.

Q: Are there any warnings about driving while taking Nan AL 110?

Official documentation focuses safety statements on its intended user group, infants aged 0–12 months.

Q: Can Nan AL 110 cause feelings of tiredness or drowsiness?

Studies have reported that the adverse events most frequently noted in earlier clinical trials included gastrointestinal issues and fatigue. Fatigue is a general term for lack of energy, but the official documents do not specifically list drowsiness as an expected side effect.

Q: What should be done if a potential interaction with another drug is found?

Official interaction statements focus on the formula’s composition, which can interfere with the absorption of certain oral medications. Regulatory documentation specifies a required time separation between the formula and sensitive oral medicinal products to mitigate the risk of reduced drug exposure.

Q: Can Nan AL 110 be split or crushed, according to official documents?

Nan AL 110 is supplied as a powder formula, not a solid pill or tablet. Official guidelines describe that the powder should be reconstituted (mixed) with water to yield the final formula immediately prior to feeding.

Q: Are there any specific lifestyle changes that are often mentioned alongside Nan AL 110 use?

Official documents specify usage constraints regarding the introduction of food. After six months of age, the formula is intended to be administered alongside the gradual introduction of natural complementary foods, as specified by the product label.

Q: Why do some people refer to Nan AL 110 as a 'second-line' treatment?

Regulatory guidance emphasizes that the formula is to be used only when medical supervision is in place and when breastfeeding is considered medically contraindicated. This suggests a specific placement within the overall dietary management protocol.

Q: Does Nan AL 110 change how other medications are absorbed?

Official regulatory documentation states that the product's interactions are classified as Absorption Interference. This is due to the formula's Polyvalent Cations (minerals) potentially interacting with certain orally administered medicinal products, which can lead to decreased systemic exposure (reduced absorption) of the medication.

Q: Is Nan AL 110 known to cause long-term side effects that appear later?

Clinical studies reported on the administration of the components over a period of time, noting the occurrence of adverse events. However, initial research examining the long-term administration of the components remains preliminary, as described in research evidence summaries.

Q: What is the official position on using Nan AL 110 with alcohol?

As the product is restricted to infants aged 0–12 months, official regulatory documents do not specify a position or provide warnings regarding the co-use of the formula with alcohol.

Q: Does Nan AL 110 treat the cause of a condition or just the symptoms?

The product's purpose is described as providing complete nutritional support. It serves as a comprehensive tool for dietary management, which includes ensuring adequate and balanced delivery of all required macro- and micronutrients.

How to Store and Dispose of Nan AL 110?

Official regulatory guidelines define specific requirements for storing and disposing of Nan AL 110 powder and prepared formula to ensure product integrity and safety.

Storage Component	Official Requirement
Powder Container Storage	Store the sealed or opened container in a cool, dry place, protected from moisture. Do not refrigerate the powder.
Powder In-Use Stability	Use the contents of an opened container within 4 weeks (or 1 month), then discard any remaining product. Always close the lid tightly after each use.
Prepared Formula Stability	Use prepared formula within 2 hours if stored at room temperature. If not used immediately, refrigerate and use within 24 hours.
Handling	Prepare formula on a clean surface. Wash hands before handling. Store the container out of the reach of children.
Disposal	Discard any prepared formula remaining in the bottle after a feeding. Dispose of unused refrigerated formula after the 24-hour limit. Follow label instructions for disposal of the empty container.